CHRISTINA BERMEA: Open Payments
NPI 1417456393 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,204 in 40 payments from 9 companies in 2025. Trend: 2023 $637 · 2024 $774 · 2025 $1,204
Food & beverage: $1,204
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $347 |
| E.R. Squibb & Sons, L.L.C. | 10 | $277 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $194 |
| Teva Pharmaceuticals USA, Inc. | 4 | $160 |
| Axsome Therapeutics, Inc. | 1 | $121 |
| Alkermes, Inc. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
Products named: VRAYLAR, COBENFY, CAPLYTA, UZEDY, Auvelity, AUSTEDO XR, LYBALVI, FANAPT.
Industry payments across TX — which companies pay providers there.
